Vertex UP 50% on Phase II results

[gebroida]

Vertex Pharmaceuticals Inc (VRTX.O) Key Developments | Reuters.com

Vertex Pharmaceuticals Incorporated: NASDAQ:VRTX quotes & news - Google Finance

Vertex Pharmaceuticals Inc Announces Interim Data From Phase 2 Combination Study Of VX-809 And KALYDECO (ivacaftor)
7:30am EDT
Vertex Pharmaceuticals Inc announced an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO™ (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies (homozygous) of the most common mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, F508del. A planned interim analysis was conducted after approximately half of the study patients had completed 56 days of treatment. Results are based on data from 37 homozygous F508del patients who completed treatment in the 56-day study and 11 patients with one or two copies of the F508del mutation who received placebo. There was a statistically significant improvement in lung function (absolute change in percent predicted FEV1) across the combined treatment groups relative to baseline compared to placebo (p=0.002). Of those who received VX-809 and KALYDECO (250mg, q12h), approximately 46% (17/37) experienced an absolute improvement from baseline to Day 56 in lung function of 5 percentage points or more, and approximately 30% (11/37) experienced an absolute improvement from baseline to Day 56 of 10 percentage points or more. None of the patients treated with placebo (0/11) achieved a 5-percentage point or more improvement from baseline to Day 56 in lung function. Most adverse events were mild or moderate in severity and comparable between treatment and placebo groups

[minnesotafarmcountry]

Ah, yes...owned it at $7 and sold it at $17? Ugh!!